Observational studyInternational journal of urology : official journal of the Japanese Urological Association2026
Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real-World Study.
Observational study in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
objectivesTo describe post-recurrence treatment patterns and outcomes after adjuvant nivolumab for urothelial carcinoma in real-world practice.
methodsWe retrospectively analyzed patients with urothelial carcinoma who underwent radical cystectomy or nephroureterectomy followed by adjuvant nivolumab in the multicenter AGEHA database. Among 141 patients, 40 developed recurrence, excluding non-muscle-invasive bladder recurrence. First-line post-recurrence treatment was categorized as enfortumab vedotin plus pembrolizumab (EVP), enfortumab vedotin (EV), non-EV regimens, or no systemic therapy. Overall survival (OS) was measured from recurrence and progression-free survival (PFS) from initiation of first-line post-recurrence therapy.
resultsOf 141 patients treated with adjuvant nivolumab, 40 (28%) developed recurrence. First-line post-recurrence treatment was EVP in 10 patients, EV in 15, non-EV regimens in 12, and no systemic therapy in 3. Median time from surgery and nivolumab initiation to recurrence was 5.9 and 4.2 months, respectively. Median OS from recurrence was 27.1, 26.0, and 23.4 months in the EVP, EV, and non-EV groups, respectively, while median PFS from initiation of first-line post-recurrence therapy was 12.9, 7.6, and 8.7 months. Baseline characteristics differed across groups, particularly in recurrence timing and metastatic sites, and EV-based therapy was frequently selected after recurrence.
conclusionsRecurrence after adjuvant nivolumab occurred in 28% of patients in real-world practice. Post-recurrence management was heterogeneous, and EV-based therapy was frequently used in this setting. These findings provide hypothesis-generating real-world evidence on treatment sequencing after adjuvant nivolumab and require validation in larger cohorts with longer follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.